Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy | Zendy

Parag Mahale | Zendy; Sheeba K. Thomas | Zendy; Andreas Kyvernitakis | Zendy; Harrys A. Torres | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy

Author(s) -

Parag Mahale,

Sheeba K. Thomas,

Andreas Kyvernitakis,

Harrys A. Torres

Publication year - 2015

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofv211

Subject(s) - medicine , thalidomide , multiple myeloma , exacerbation , hepatitis c virus , sofosbuvir , chemotherapy , virus , immunology , virology , ribavirin

Reactivation of chronic hepatitis C virus (HCV) infection has been reported in cancer patients receiving chemotherapy. In this study, we report the first case, to our knowledge, of thalidomide-induced acute exacerbation and reactivation of chronic HCV infection complicating management of multiple myeloma. Sofosbuvir-based antiviral therapy helped achieve viral clearance and normalization of liver enzymes, thus allowing access to future potentially life-saving chemotherapy agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research